Max Robotics — Global Service Robot Directory + US Certification

About

Dr. A. Weissferdt is a leading pathologist whose research focuses on thoracic malignancies, particularly lung cancer. A key contributor to the NEOSTAR clinical trial, Dr. Weissferdt co-authored the highly cited study "Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer," which demonstrated the safety and efficacy of combining immunotherapy with surgery. This work has garnered 28 citations and has significantly influenced neoadjuvant treatment paradigms for non-small cell lung cancer. Dr. Weissferdt’s expertise lies in correlating pathological responses with clinical outcomes, providing critical insights into how immunotherapy reshapes the tumor microenvironment. Their research bridges surgical oncology and immunology, offering a deeper understanding of how to optimize multimodal therapy for lung cancer patients. With a career dedicated to advancing precision pathology, Dr. Weissferdt continues to shape the landscape of thoracic oncology through rigorous translational studies.